A novel quantitative liver function test is described which is based on monoethylglycinexylidide (MEGX) formation after lidocaine bolus injection. Following the administration of small single doses of lidocaine hydrochloride (l mg/kg), monoethylglycinexylidide serum concentration-time curves were determined by a novel highly sensitive fluorescence Polarisation immunoassay (FPIA) in healthy volunteers, liver donors and patients with liver cirrhosis. The FPIA allowed rapid and reliable monoethylglycinexylidide determinations in serum and urine (between-days coefficient of Variation: < 10.3%, recovery: 80-113%). Monoethylglyci- nexylidide concentrations measured by FPIA in 32 serum samples from patients correlated well those determined by HPLC. The monoethylglycinexylidide concentration in serum determined 15min after a lidocaine bolus injection proved to be a highly sensitive and specific indicator of hepatic dysfunction. Average monoethylglycinexylidide concentrations in serum obtained 15 min after lidocaine injection were substantiälly lower in patients with liver cirrhosis than in healthy volunteers. The average monoethylglycinexylidide concentrations in serum were also substantiälly lower in liver donors with ballooning or fatty changes of hepatocytes than in donors without relevant alterations of liver histology. By means of 'monoethylglycinexylidide formation in the liver donors, primary function of the transplanted liver was correctly predicted in 32/37 cases and initial non-function in 4/6 cases.
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Introduction
In the past few years, liver transplantation has gained increasing importance for the treatment of liver failure in acute and chronic liver disease. This development has created a great demand for suitable tests for the assessment of liver function particularly in liver allograft donors and recipients.
Assessment of liver function is essential in potential liver donors in order to avoid transplantation of organs with a high risk of initial non-function. Macroscopic appearance, clinical chemical analyte determinations (e. g. aspartate aminotransferase, bilirubin) and common quantitative liver function tests (e. g. indocyanine green (1) or galactose (2) elimination) often fail to provide sufficient prognostic Information (3, 4) . In a previous study Forrest et al. (5) reported that in patients with chronic liver disease elimination of lidocaine was much more affected than that of antipyrine and paracetamol. Therefore these authors concluded that the half-life of lidocaine is a highly sensitive indicator of hepatic dysfunction. Recently it has been suggested that the formation kinetics of the lidocaine metabolite monoethylglycinexylidide (MEGX) could be used in the evaluation of liver function (6) .
Lidocaine is metabolized by the liver and only about 3% of the dose is excreted äs intact drug in the urine over 24 hours (7) . Monoethylglycinexylidide ( fig. 1 ) is formed from lidocaine via oxidative N^deethylation by the hepatic cytochrome P-450 System (8). Monoethylglycinexylidide, which is further metabolized to glycinexylidide and 4-hydroxy-2,6-xylidine, is found only in small quantities (about 4% of the lidocaine dose) in the urine (7) . The pharmacokinetics and pharmacodynamics of monoethylglycinexylidide have recently been studied in healthy subjects (9) .
The present study was designed to investigate the clinical usefulness of monoethylgiycinexylidide formation kinetics for the assessment of liver function. For this purpose monoethylglyeinexylidide serum concentration-time curves were determined by use of a novel highly sensitive fluorescence Polarisation immunoassay (FPIA) in healthy volunteers, liver donors and patients with liver cirrhosis. A further aim of the study was to assess the äccuracy of the FPIA by comparison with HPLC. Monoethylglycinexylidide concentrations in serum following lidocaine bolus injection were studied for possible correlation with the morphological features of liver grafts.
Materials and Methods

Study design
Venous blood "was taken from 16 healthy volunteers and 13 patients with histologically confirmed liver eirrhosis at 2, 5,10, 15, 20, 30, 60, 120, 180, 240 and 300 min after bolus injection of l mg/kg lidocaine hydrochloride (Xylocaine® solution 20 g/l; Astra Chemicals, Wedel, F. R. G.). Durrag the fürst hour after lidocaine injection the healthy volunteers and the patients were in a recumbent position. Urine samples were collected at intervals of 3 h over a period of 24 h. In addition, the 15 min monoethylglycinexylidide concentrations in serum were determined in 12 fully rehabilitated liver recipients, who had survived liver transplantation for l to 12 years. Test subjects participated in. the study after giving written infonned consent.
In 48 liver donors with confirmed brain death, resülting from head injury or intracranial haemorrhage, blood was taken before äs well äs 15, 30 and 60 min after an intravenous lidocaine (Xylocaine®) bolus iajection (l mg/kg). The investigations on monoethylglyeinexylidide formation kinetics were part of a collaborative study on the assessment of donor suitability which was approved by the local Ethics Comnaittee. 
Detection limit of fluorescence polarisation immunoassay
A series of 20 zero calibrator samples was analysed by fluorescence polarisation immunoassay. The 'mean and Standard deviation of the observed fluorescence polarisation values were calculated. The calibration curve was used to determine the monoethylglycinexylidide concentration which corresponded to the fhiorescence polarisation obtained by subtraction of the three^fold Standard deviation from the mean. In aceordance with a definitipn by Kaiser (11) this value was regarded s the detection limit of the assay.
High performance liquid chromatography (HPLC)
HPLC was performed by a modification of a procedure described by Nation et al. (12) . To l ml of serum or Standard in a glass conical tube were added: 100 μΐ of internal Standard solution (1.25 mg/1 tocainide in water), 100 μΐ of l mmol/1 NaOH, and 3 ml of ethylacetate. The tubes were shaken mechanically for 1min (Multivortex), centrifuged at 1000g for 5min, and the upper (organic) phase was transferred into a clean glass conical tube. Then 100 μΐ of 0.01 mol/1 HC1 was added, and the tubes were shaken and centrifuged s described above. An aliquot of 40 μΐ from the lower (aqueous) phase was injected into the Chromatograph.
The Chromatographie System consisted of a Hewlett Packard HP 1090 equipped with an automatic sample injector, a heated oven compartment, a diode-array-detector, and a 3392 A digital integrator. Chromatography was performed on a reversedphase C 8 
Specificity of FPIA
The specificity of the FPIA was assessed by adding lidocaine and major metabolites of this compound to drug-free human serum. No significant eross-reactioiis were found with lidocainej glycinexylidide and 4^hydroxy-2,6-xylidine (tab. 3). 2) Concentration producing a response in the FPIA equivalent to 0.03 mg/1 monoethylglycinexylidide.
Detection limit
The detection limit fbr monoethylglycinexylidide was 11 μ §/1 with the fluorescence Polarisation immunoassay.
Monoethylglycinexylidide concentrations in serum after lidocaine bolus injection
In figures 5, 6 and 7 the formation and elimination kinetics of monoethylglycinexylidide are shown for healthy volunteers* patients with histologically confirmed liver cirrhosis and liver doriors after administration of single intravenous lidocaine bolus injections (l mg/kg). To exclude patients with previous lidocaine therapy, only data from those subjeets with monoethylglycinexylidide predose serum concentrations below the detection limit of the fluorescence Polarisation immunoassay were included in these figures. There was a rapid increase of monoethylglycinexylidide concentration in serum within the first 15 min after lidocaine administration in normal subjeets ( fig.  5 ). The highest serum concentrations of this metabolite were measured 15 min after lidocaine injection. In one of the healthy subjects only relatively low monoethylglycinexylidide concentrations were observed. This subject excreted a relatively large amount of monoethylglycinexylidide within the first three hours after lidocaine injection (94 g per kg body weight). In all the other healthy volunteers (n = 15) tested the average urinary excretion of monoethylglycinexylidide during this period was only 20.7 g per kg body weight (ränge: 2.0-45.0 g/kg).
In patients with liver cirrhosis the rate of monoethylglycinexylidide formation from lidocaine was substantially decreased ( fig. 6 ). Therefore the averaged concentration-time curve observed in these patients was different from that obtained in healthy subjects. Within the first 15 minutes only very low serum concentrations of monoethylglycinexylidide were found. Maximal serum concentrations of this metabolite were observed at about 240 min after lidocaine injection. In these patients (n = 13) the average urinary excretion of monoethylglycinexylidide within the first 3 hours after lidocaine administration was only 4.0 g per kg body weight (ränge: 0.2-10.0 g/kg).
In fully rehabilitated liver recipients (n = 12), the 15 min monoethylglycinexylidide concentrations in serum (median: 97 g/l; ränge: 54-155 g/l) were in the ränge observed in normal subjects ( fig. 5 ).
In liver donors, the average monoethylglycinexylidide concentrations in serum, determined 15, 30 and 60 min after lidocain bolus injection, were significantly (p < 0.05) higher than the corresponding values obtained in normal subjects ( fig. 5, 7 ). percentile (68 percent of values). The median is indicated by the horizontal line in each box.
Monoethylglycinexylidide concentrations in serum 15 min after i. v. lidocaine bolus injection were on average distinctly higher in donors with normal liver histology than in those with ballooning or fatty changes of hepatocytes and patients with liver cirrhosis. In 37 accepted organs, initial liver function and initial nonfunction were correctly predicted by means of monoethylglycinexylidide in 32 cases. Initial non-function of the liver following transplantation was observed 6 times. In four cases this event was correctly predicted by means of monoethylglycinexylidide.
Eleven donor organs were not transplanted because of their macroscopic appearance. Six out of eleven cases showed normal histology and normal monoethylglycinexylidide formation. In 3/11 cases pathological fmdings of monoethylglycinexylidide and histology were observed. The remaining 2 cases had normal monoethylglycinexylidide values but pathological histology.
Discussion
The results of our study demonstrate that the described fluorescence Polarisation immunoassay is suitable for determination of the low monoethylglycinexylidide concentrations present in serum after small lidocaine hydrochloride test doses of l mg per kg body weight. A comparison of the results determined by fluorescence Polarisation immunoassay with those ob* tained by high performance liquid chromatography showed a satisfactory cörrelation between both methods ( fig. 4 ). Our study on monoethylglycinexylidide formation kinetics confirms previous reports regarding the dependence of lidocaine elimination on liver function (5, 14, 15) . In general a monoethylglycinexylidide cpncentration in serum determined 15 min after a lidocaine bolus injection seems to reflect well the initial formation rate of this metabolite ( fig. 5, 6 ). So far, only one case has been encountered, in which the 15 min monoethylglycinexylidide conceiitration in serum was affected by an unusually high urinafy excretion of this metabolite.
The monoethylglycinexylidide concentrations in serum, measured 15 min after lidocaine bolus injeetion, were on average significantly higher in liver donors than in normal subjects ( fig. 5, 7 ). At present it may only be speculated that this phenomenon is due to an induction of lidocaine metabolism and/or an increased hepatic blood flow in donors caused by other therapeutically administered drugs.
As shown in figure 8 the monoethylglycinexylidide concentration in serum determined 15 min after a lidocaine test dose was a highly sensitive and specific indicator of hepatic damage. Measurement of initial monoethylglycinexylidide concentrations in serum allowed a satisfactory differentiation between the population of patients with liver cirrhosis and that of donors with normal liver histology. Monoethylglycinexylidide concentrations observed in donors with less prominent histological changes showed some overlap with the concentrations of monoethylglycinexylidide determined in both groups of donors with normal histology and patients with liver cirrhosis. More data are needed to define a meaningful "cut-off value to distinguish between the presence and absence of liver damage. So far the "cut-off has been empirically set at a monoethylglycinexylidide concentration in serum of 50 §/1, since concentrations below this value were generally associated with hepatic impairment (4).
Preliminary data on survival rates of recipients of primary liver transplants indicate that monoethylglycinexylidide formation may provide valuable prognostic Information. A significant difference (p < 0.005) was observed in survival between recipients of allografts from donors with monoethylglycinexylidide concentrations in serum above 90 g/l and those with concentrations of this compound below this value (16) . Donor rating with normal or pathologic indocyanine green clearance äs well äs normal and pathologic galactose elimination capacity, however, failed to give satisfactory prognostic Information. One to twelve years after transplantation, fully rehabilitated liver recipients showed 15 min monoethylglycinexylidide serum concentrations similar to those found in healthy volunteers.
Further evidence regarding the usefulness of the described approach for the assessment of liver function was recently obtained in a comparative study with various established liver function tests (e. g. indocyanine green clearance, galactose elimination capacity). It was demonstrated that a single monoethylglycinexylidide serum concentration determined in liver donors 15 min after intravenous administration of a lidocaine test dose häd a distinctly higher predictive value for the assessment of primary non-function of the subsequently transplanted liver than all the other liver function parameters tested (4).
It appears that certain specific drug-metabolizing pathways are sensitive to hepatocellular injury. Based on N-demethylation, for example, an aminopyrine breath test was developed (17, 18) , which permits the detection of even minor hepatic injuries. In a modification of this concept we have chosen monoethyl-glycinexylidide formation after lidocaine injection äs indicator of liver function. It has been demonstrated that monoethylglycinexylidide formation depends mainly on hepatic cytochroine P-450-mediated Ndeethylation (8, 19 In a further study with liver donors the results of the monoethylglycinexylidide test were compared with those of indocyanine green clearance and galactose elimination capacity. A differentiation between normal and pathologic donor liver histology was only possible with the monoethylglycinexylidide formation test (16) .
Lidocaine at the low doses used in our study appears to be a safe test compound. It has to be considered, however, that this substance can produce anaphylactic reactions (21). For liver donors or recipients, however, this problem is of relatively low singificance since these patients are closely monitored at intensive care units. So far in our study adverse reactions, other than slight drowsiness in patients with severe hepatic impairment, were not observed;. rln comparison with other liver function tests, such äs the aminopyrine breath test (22) or bromosulphqphthalein test (23), the risk of serious side effects appears to be considerably löwer with the described lidocaine test.
The fluorescence Polarisation immunoassay is rapid and easy to perform. A single serum sample from a patient can be analysed within about 20 min. Therefore this assay is very convenient for the assessment of liver quality in potential donors, since the results can be made available eärly before transplantation. This aspect is of particular importance beeause histologically and functionally intact organs are often not transplanted beeause of macroscopic appearance.
In our study we observed that 55% of the livers not accepted for transplantation beeause of macroscopic appearance would have been suitable for transplantation according to histology and the described lidocaine liver function test,
From the results of our study it is concluded that the analysis of hepatic monoethylglycinexylidide formation is a promising new approach for rapid assessment of hepatic function, particularly in liver donors. A prospective study is currently in progress at our hosp ital to further investigate the diagnostic and pfognostic value of this test.
